机构：[1]Department of Ophthalmology, Peking University People's Hospital, Eye diseases and Optometry Institute, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University Health Science Center, Beijing 100044, China.[2]Department of Ophthalmology, Beijing Jingmei Group General Hospital, Beijing 102300, China.[3]Department of Ophthalmology, Hebei General Hospital, Shijiazhuang 050051, Hebei Province, China.[4]Xiamen Eye Center of Xiamen University, Xiamen 361003, Fujian Province, China.
To assess the efficacy of intravitreal triamcinolone (IVTA) as an adjunct to the combination of anti-vascular endothelial growth factor (VEGF) for the management of diabetic macular edema (DME).A total of 51 patients with visual disabilities causing by DME from two sites were retrospectively collected and assigned to two groups according to the therapeutic method: intravitreal conbercept (IVC) combined with focal laser (24 eyes) and IVC combined with focal laser and IVTA (27 eyes). Best-corrected visual acuity (BCVA), the required number of IVCs, central retinal thickness (CRT), the mean costs of treatment burden and safety were compared over 12mo.From baseline to month 1 through month 12, IVC combined with focal laser and IVTA improved the mean average change in BCVA superior to IVC combined with focal laser (+5.20 vs +2.71 letters). At month 12, 20.83% of the IVC combined with focal laser and 37.04% of IVC combined with focal laser and IVTA arms gained more than 10 BCVA letters. During the period, the mean CRT decreased significantly in the IVC combined with focal laser and IVTA arm (-245.9 µm) compared to the IVC combined with focal laser arm (-98.45 µm). The average of 6.45 and 1.25 conbercept injections performed in the IVC combined with focal laser and IVC combined with focal laser and IVTA arms, respectively. The mean cost of treatment burden for 12mo was $6247.44±4069.18 in the IVC combined with focal laser arm and $1679.19±542.73 in the IVC combined with focal laser and IVTA arm, with a statistically significant difference. Apart from occasional minor subconjunctival hemorrhage, no other significant ocular adverse events (AEs) were observed in either group during the12-month period.It is effective and cost-effective to treat DME by utilizing triamcinolone as an adjunct to the combination of anti-VEGF.International Journal of Ophthalmology Press.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2020]版：
大类|3 区医学
小类|3 区眼科学
最新[2025]版：
大类|4 区医学
小类|3 区眼科学
第一作者：
第一作者机构：[1]Department of Ophthalmology, Peking University People's Hospital, Eye diseases and Optometry Institute, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University Health Science Center, Beijing 100044, China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Ophthalmology, Peking University People's Hospital, Eye diseases and Optometry Institute, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University Health Science Center, Beijing 100044, China.[4]Xiamen Eye Center of Xiamen University, Xiamen 361003, Fujian Province, China.[*1]Department of Ophthalmology & Clinical Centre of Optometry, Peking University People's Hospital, 11 Xizhimen South Street, Xicheng District, Beijing 100044, China
推荐引用方式(GB/T 7714)：
Yu Ying-Ying,Cheng Yong,Chang Li-Bin,et al.Triamcinolone as an adjunct to the combination of anti-VEGF for the management of diabetic macular edema.[J].International Journal of Ophthalmology.2021,14(6):869-874.doi:10.18240/ijo.2021.06.12.
APA：
Yu Ying-Ying,Cheng Yong,Chang Li-Bin,Xia Hui-Ka&Li Xiao-Xin.(2021).Triamcinolone as an adjunct to the combination of anti-VEGF for the management of diabetic macular edema..International Journal of Ophthalmology,14,(6)
MLA：
Yu Ying-Ying,et al."Triamcinolone as an adjunct to the combination of anti-VEGF for the management of diabetic macular edema.".International Journal of Ophthalmology 14..6(2021):869-874
